Posters

Clinical and functional results of bifocal refractive-diffractive and diffractive aspheric IOLs with asymmetric optic implantation during combined cataract and glaucoma surgery with lens capsule drainage

Poster Details

First Author: O.Mijovich RUSSIA

Co Author(s):    K. Pershin   N. Pashinova   A. Tsygankov   G. Solovyova           

Abstract Details

Purpose:

Comparative analysis of the clinical and functional results of bifocal refractive-diffractive and aspheric diffractive IOL with asymmetric optics implantation during combined cataract and glaucoma surgery.

Setting:

Eximer Eye Center, Moscow, Russian Federation

Methods:

41 patients (75 eyes) with presbyopia and primary open angle glaucoma who underwent one-stage cataract phacoemulsification with implantation of a multifocal IOL and NDPS with lens capsule drainage were included in a prospective study. Group I included 24 patients (44 eyes) with implantation of diffractive-refractive IOL AcrySof�Â�® IQ ReSTOR�Â�® SN6AD1 with the addition of �.0 diopters for near vision. Group II consisted of 17 patients (31 eyes) who were implanted with aspherical diffractive intraocular lens optics with asymmetric Lentis Mplus LS-313MF-30 with an add power of �.0 diopters for near vision.

Results:

Mean IOP in both groups was 18.1�Â�±2.9 mm Hg, difference with the preoperative parameters (26.1�Â�±2.8) was statistically significant (p <0.05). Patients received 1.3�Â�±0.5 antihypertensive drug compared to 2.4�Â�±0.61 before surgery (0.05

Conclusions:

In this paper we analyzed in comparison clinical and functional results of bifocal refractive-diffractive and aspheric diffractive IOL with asymmetric optics implantation during the combined cataract and glaucoma surgery for the first time. The main study goal (BCVAfd = 1.0 at 1 year after surgery) was achieved in 31.8% of cases in group I and in 29.1% of cases in group II (p>0.1). Implantation of multifocal IOL in the combination cataract and glaucoma surgery is a safe and effective surgical intervention in this group of patients.

Financial Disclosure:

NONE